Results 21 to 30 of about 14,564 (189)

Aflibercept clearance through the drainage system in a rat model

International Journal of Retina and Vitreous, 2021
Background As intravitreal anti-VEGF injections became the mainstay of treatment for many retinal diseases, the cause of a secondary sustained elevated intraocular pressure is still unclear.
Yariv Keshet, Orly Gal-Or, Michal Schaap Fogler, Karin Mimouni, Meydan Ben Ishai, Dov Weinberger, Assaf Dotan   +6 more
doaj   +1 more source

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD

Molecular Therapy: Methods & Clinical Development, 2023
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness in the aging population, with vascular endothelial growth factor (VEGF) playing a key role. Treatment with recombinant anti-VEGFs is the current standard of care; however,
Sharifah Iqball, Daniel K. Beck, Gayathri Devarajan, Cheen P. Khoo, Deirdre M. O’Connor, Scott Ellis, Efrain Guzman, Kyriacos A. Mitrophanous, Yatish Lad   +8 more
doaj   +1 more source

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations

International Journal of Retina and Vitreous, 2017
Background The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept.
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen   +3 more
doaj   +1 more source

Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer [PDF]

Farmacia Hospitalaria, 2014
Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin.
M.ª Echave, C. Pericay, C. Frías, A. Abad, M.ª J. Lamas, I. Oyagüez, M. Rubio, M. Rubio, E. Giménez, S. Naoshy, F. Joulain   +10 more
doaj   +1 more source

Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma

Journal of Experimental & Clinical Cancer Research, 2016
Background To evaluate the inhibitory effects of aflibercept on the growth and subretinal invasion of retinoblastoma. Methods Xenotransplantation and orthotopic mouse models were created by injecting Y-79 cells subcutaneously and intravitreally ...
Dong Yoon Kim, Jeong A Choi, Jae-Young Koh, Young Hee Yoon   +3 more
doaj   +1 more source

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration

Delhi Journal of Ophthalmology, 2021
Introduction: To assess whether switching from Ranibizumab to Aflibercept conferred benefit in visual acuity (VA) and central macular thickness (CMT) in patients with wet age-related macular degeneration (AMD).
Bhagya Weerasinghe, Chandni Gupta, Yasmin Levene, Jai Shankar   +3 more
doaj   +1 more source

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Molecular Therapy: Methods & Clinical Development, 2020
Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance resulting ...
Szilárd Kiss, Ruslan Grishanin, Aivan Nguyen, Romeo Rosario, Judith S. Greengard, Julio Nieves, Claire M. Gelfman, Mehdi Gasmi   +7 more
doaj   +1 more source

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2016
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF ...
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano   +11 more
doaj   +1 more source

Comparison of Loading Doses of Ziv-Aflibercept and Aflibercept in Neovascular Age-Related Macular Degeneration [PDF]

, 2020
Purpose:The aim of this study was to compare outcomes of 3 loading doses of ziv-aflibercept and aflibercept in treatment-naïve neovascular age-related macular degeneration (nAMD).Design:Retrospective, nonrandomized, comparative study.Methods:This was a ...
Subramanyam, Anand, Pandey, Priti, Chhablani, Jay Kumar, Abhishek Heranjal, Apoorva Ayachit, Tiwari, Sarvesh, Jay Chhablani, Heranjal, Abhishek, Sarvesh Tiwari, Salti, Haytham I.S., Priti Pandey, Ahmad Mansour, Ayachit, Apoorva G., Mansour, Ahmad Mohammed Farid Mahmoud, Chattannavar, Goura, Goura Chattannavar, Mohamad A Mansour, Sumit Randhir Singh, Anand Subramanyam, Haitham Salti, Singh, Sumit Randhir, Mansour, Mohamad A.   +21 more
core   +1 more source

El efecto del agente antiangiogénico aflibercept sobre la endometriosis inducida quirúrgicamente en un modelo de rata

Cirugía y Cirujanos
Objetivo: Mostrar por primera vez cómo afecta aflibercept a las lesiones de endometriosis. Material y métodos: Endometriosis inducida quirúrgicamente en ratas hembras albinas Wistar. Las ratas con endometriosis se dividieron aleatoriamente en tres grupos:
Caglayan Ates, Berna Dilbaz, Seval Yılmaz Ergani, Fuad Atabay   +3 more
doaj   +1 more source